“We founded reVision Therapeutics to reimagine the drug development lifecycle by finding new life for existing products to treat high-impact ophthalmic diseases.”
The reVision Promise:
A Socially Conscious Business Model
Develop ophthalmic products to treat inadequately met needs for high-impact diseases.
Mitigate risk by repositioning existing products: we repurpose approved drugs and rescue shelved drugs.
Reduce cost by securing stakeholder support for development and commercialization.
Expand accessibility by passing cost savings to consumers to ensure sustainable business.
What We Do
Commitment to Patients
Each ophthalmic medicine reVision develops addresses an unmet or poorly met need, irrespective of that medicine’s potential to offer traditional patent or pricing exclusivity.
Commitment to Access
reVision reduces development cost by repositioning existing products and passes this saving directly to the consumers via lower cost and simplified access. reVision’s unique adoption model seeks patient, doctor, and payer commitments during development to facilitate early product adoption in return for prices that encourage access.
Commitment to Change
By finding a new way to commercialize, reVision seeks to improve the drug price paradigm through free market competitive pressure, shifting the debate on drug costs away from imposing price controls and undermining patents and innovation.
Media & Events
X (formerly Twitter)
Events
No upcoming events.
